Skip to main content
MGTX logo

MGTX · MeiraGTx Holdings plc

Track MGTX — free
$10.92 +0.00 (+0.00%)
Market Cap
$1.05B
Shares
96.04M
Volume · Oct 5 941.65K Avg daily vol (3M) 788.63K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$10.92 Open$10.77 Day$10.59–11.03 52W close$6.99–14.97 Avg vol 30d921K Short int4.0M · 4.2% float · 6.1d Short vol77% Last earningsApr 16, 2026 DataJan 2020–Oct 2026 Filing10-Q · Aug 13

Up next

filed Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$397.50M
Trailing 12 months
Net income (TTM)
$78.98M
Trailing 12 months
Revenue growth YoY
+8,608.6%
Year over year
Operating margin
46.3%
Trailing 12 months
P / E (TTM)
15.2
Trailing earnings · reciprocal yield 6.6%
FCF yield
1.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$143.17M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+16.4%
Year over year · more shares
Price change (1Y)
+28.5%
Trailing year
Short interest
4.2%
Latest settlement · 6.1 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 15.5 · calm Equity put/call 0.59
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +8%
above
Price vs 50-day avg −15%
below
RSI (14) 31
neutral
MACD trend Negative
52-week position 49%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return −21%
trailing
6-month return −3%
trailing
YTD return +37%
this year
Relative strength −15%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $13 › 200d $10 — 50d above 200d
Institutional flow Flat
1 of 158 funds reported for Sep 30 · net 0 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
4.18% of float · ▲ +7.7% MoM · 6.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
158 holders — near 3-yr high, broad support
Squeeze score 62
elevated · 0–100
Fundamentals
Strong
Revenue growth +145%
Y/Y
EPS growth +33%
Y/Y
Free cash flow $-50.2M
Valuation P/E 15.4
in line
Buyback $18.2M
authorized
Quant / Vol
risk profile
Very High
Volatility 59%
annualized · 1-yr
Max drawdown −29%
past year
ATR 5.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+8% Bullish
Price vs 50-day avg
−15% Bearish
RSI (14)
31 Neutral
MACD trend
Negative Bearish
52-week position
49% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $13 › 200d $10 — 50d above 200d
Institutional flow Flat
1 of 158 funds reported for Sep 30 · net 0 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
4.18% of float · ▲ +7.7% MoM · 6.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
158 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $7 Now $11 · 49% Range high $15
vs 200-day avg +8% vs 50-day avg -15%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MGTX
MeiraGTx Holdings plc
this stock
$1.05B +37.4% +144.6% 15.4 4.2%
VRTX
Vertex Pharmaceuticals Inc / Ma
$133.37B +11.1% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$81.13B -5.9% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
$79.40B +589.1% +4.3% — 8.2%
CSLLY
Csl Ltd
$61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders
Holders
158
% held
82.6%
Reported
1 of 158
Top holder
Sanofi
Held Float
View
Held by Funds
Fund positions
47
View
Short & Settlement
Short Interest Rising
Shares short
4.0M
Days to cover
6.1d
Change
+288.5K sh
View
Short Volume
Short vol %
77%
As of
Oct 5, 2026
Short Total
View
Fails to Deliver
FTD shares
220
Value
$2.8K
As of
Sep 11, 2026
View
Off-Exchange
Off-exchange %
41.9%
Week of
Aug 31, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$81.4M
Net income (FY)
$-114.2M
EPS diluted
$-1.42
View
Buybacks
Authorized
$18.2M
View
Filings
SEC Filings
Latest
8-K
Filed
Sep 23, 2026
This year
16
View
Proposed Sales
Value
$859.3K
Shares
62.0K
Filed
Aug 18, 2026
View
Earnings & Events
Webcasts
Last webcast
Jun 4, 2026
View

Performance

5D 20D 120D MTD YTD
MGTX -1.7% -21.4% -3.3% -0.7% +37.4%
SPY +1.2% +0.6% +11.6% +1.6% +13.6%
vs SPY -2.9% -22.0% -14.9% -2.3% +23.7%

Capital returns

Buyback program · as of Dec 31, 2025
Authorized
$18.20M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1735438 CUSIP G59665102 13F (30d) 5 filings 5 filers Visit website Investor relations